山东步长制药股份有限公司关于公司董事辞职的公告

Group 1 - The resignation of director Zhao Chao from the company's board of directors has been accepted due to personal reasons, and his departure will not affect the board's operation or the company's normal business [2][4][5] - Zhao Chao did not hold any shares in the company and there were no significant disagreements or unfulfilled commitments [2][4] Group 2 - The company plans to transfer 0.50% equity of its subsidiary Shandong Buchang Chuanfang Pharmaceutical Co., Ltd. to He Tao for a price of 0.6875 million RMB, while also agreeing to waive its right of first refusal [4][5][6] - The net asset value of Buchang Chuanfang as of July 31, 2025, was reported at 1.375 million RMB [4][6] Group 3 - The company has signed agreements for the equity transfer and cooperation regarding the subsidiary Shandong Buchang Yaoguan Biotechnology Co., Ltd., where Zhao Lu will transfer 1.50% of unpaid equity to the company at a price of 0 RMB [16][17][18] - After the transfer, the company will hold 94.50% of the equity in the subsidiary [16][18] Group 4 - The company has agreed to waive its right of first refusal for the transfer of 3.00% equity in Shandong Buchang Dingsheng Pharmaceutical Co., Ltd. at a total price of 4.2366 million RMB [28][29] - The net asset value of Buchang Dingsheng as of July 31, 2025, was reported at 1.4122 million RMB [28][29]